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ABSTRACT
Introduction: This study was conducted using
an integrated retrospective database to evaluate
the effectiveness of Omnitrope (Sandoz) on
children with growth hormone deficiency
(GHD), idiopathic short stature (ISS), and
Turner Syndrome (TS) who switched from a
non-Omnitrope recombinant human growth
hormone (rhGH) preparation during routine
clinical care.
Methods: This was a retrospective study which
identified patients with GHD, ISS, and TS
during the study time period of January 1,
2006 and July 31, 2011. Patients were included
if they switched to Omnitrope from another
non-Omnitrope rhGH therapy during the study
time period, were \18 years of age at time of
switch, and on a prior rhGH therapy for at least
15 months pre-switch and on Omnitrope for
15 months post-switch. Auxological parameters
(height, height standard deviation score [HSDS],
height velocity [HV], and height velocity
standard deviation score [HVSDS]) were
evaluated during post-switch.
Results: One hundred and three patients were
identified: GHD (n = 57), ISS (n = 26), and TS
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(n = 20). There was continuous growth in
height for all 103 patients with an average rate
of 6.52 cm over the 15-month post-switch
period. Patients with GHD grew an average
rate of 6.30 cm, patients with ISS grew an
average rate of 6.58 cm, and patients with TS
grew an average rate of 6.52 cm over the
15-month post-switch period. The average rate
of HSDS was increased by 0.04 for all patients.
The HV and HVSDS demonstrated the expected
decline with advancing age and prolonged
duration of treatment.
Conclusions: The growth trajectories of
rhGH-treated patients were not negatively
impacted by switching to Omnitrope and
growth rates remained as expected prior to
the switch.
Keywords: Biologics; Children; Growth
hormone deficiency (GHD); Idiopathic short
stature Omnitrope; Recombinant human
growth hormone (rhGH); Switching; Turner
syndrome
INTRODUCTION
There are currently nine recombinant human
growth hormone (rhGH) products available in
the USA for ten different indications [1]. Most of
these rhGH products are approved for one or
more indications. Growth hormone deficiency
(GHD), idiopathic short stature (ISS), and
Turner syndrome (TS) are some of the
indications for which an rhGH is prescribed.
Patients with GHD or ISS make up the majority
of the pediatric population receiving growth
hormone treatment [1]. GHD affects *1 in
3,500 children [2]. In 2003, the Food and Drug
Administration approved rhGH for children
with ISS whose height is more than 2.25
standard deviations (SD) below the mean (or
below the 1st percentile). Since the specific
etiology for ISS in children is sometimes
difficult to identify, children are often
diagnosed with ISS and receive growth
hormone (GH) therapy [3, 4]. TS occurs *1 in
2,000–2,300 live female births [5].
Omnitrope (Sandoz) is one of the rhGH
products available in the USA. It was developed
as a medicinal product similar to the reference
rhGH product, Genotropin (Pfizer Inc.). Long-
term studies comparing Omnitrope and
Genotropin have shown similar efficacy and
safety [6–9]. Physicians are often confronted
with the need to change the rhGH used by their
patients due to health plan and/or patients’
insurance demands. Thus, there is a need for
data demonstrating what impact switching
rhGHs has on patients’ auxological
measurements. During 2009, Kaiser
Permanente Southern California (KPSC) had a
formulary change which transitioned patients
on other rhGHs to Omnitrope, thus providing a
unique opportunity to evaluate the effects of
switching preparations.
The primary objective of this study was to
evaluate the effectiveness of Omnitrope on
children with GHD, who switched from a
non-Omnitrope rhGH preparation during
routine clinical care. Secondary objectives
were to evaluate the effectiveness of
Omnitrope on children with an alternative
diagnosis such as ISS or TS. This study
considered quantitative outcomes evaluating
change in auxological parameters such as
height, height standard deviation score
(HSDS), height velocity (HV), and height
velocity standard deviation score (HVSDS)
from time of their switch to Omnitrope until
15 months post-switch.
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METHODS
Setting
KPSC is a non-profit, group-model, health
maintenance organization (health plan)
providing integrated healthcare services to
more than 3.6 million active members in
Southern California, USA. The health plan
covers the seven most populous counties in
Southern California, from Los Angeles south to
San Diego and east to the inland counties of
Riverside and San Bernardino. KPSC
membership closely mirrors the Southern
California population, is racially diverse and
includes the entire socioeconomic spectrum
[10, 11]. Patient information on demographics
and healthcare encounters (diagnoses,
procedures, laboratory results, and
prescriptions) are captured in the KPSC
electronic medical record (eMR) system. KPSC
members receive the majority of their
healthcare and prescriptions at Kaiser
Permanente facilities, which provides an ideal
environment to conduct research studies.
Study Design and Patients
This retrospective cohort design study was
conducted for the KPSC region only and was
approved by the KPSC Institutional Review
Board. Patients included in the study had
GHD, ISS, or TS, and were switched to
Omnitrope from another non-Omnitrope
rhGH therapy between January 1, 2006 and
July 31, 2011. We identified GHD, ISS, or TS by
International Classification of Diseases, Ninth
Revision Clinical Modification (ICD-9-CM) of
253.xx (GHD), 783.xx (ISS), and 758.6 (TS).
Each chart was then further reviewed to
evaluate the diagnosis and code. Index date
was defined as the date the patient switched
from non-Omnitrope rhGH to Omnitrope. Pre-
switch was defined as 15 months prior index
date and post-switch as 15 months duration
after the index date. Additional inclusion
criteria were continuous membership and drug
benefit eligibility in KPSC for 15 months
pre-switch and 15 months post-switch;
age \18 years on index date; and in receipt of
a non-Omnitrope rhGH therapy for 15 months
pre-switch. The 15-month pre-switch criteria
were incorporated to limit potential bias
associated with ‘‘catch-up growth’’ that is
observed during initial GH therapy. The study
observation period ended on October 31, 2012
so that each patient had a 15-month post-
switch follow-up period. Patients had to have at
least three documented visits that were
3 months apart in the 15 months pre-switch
and at least three visits that were 3 months
apart in the 15 months post-switch. The visits
had to span more than 9 months before and
after the index date. Once the initial cohorts
were assembled, patients were further
categorized according to their pubertal stage
via Tanner staging [12, 13]. Patients with a
Tanner stage of \2 were categorized as pre-
pubertal and patients with Tanner stage of C2
categorized as pubertal.
Efficacy Assessments
The primary study outcomes were auxological
changes in height, HSDS, HV, and HVSDS from
the index date to 15 months post-switch. The
height measurement closest to the index date
was the baseline value. All patients had their
baseline height value within 7 days prior to
switching to Omnitrope. HV (cm/year) was
calculated as the difference between two
height measurements divided by the time
interval between these two measurements
multiplied by 365.25. Standardization of
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height used US Centers for Disease Control and
Prevention reference ranges of body height and
the mean and SD ranges of normally growing
children [14] taken from tables provided by
Tanner et al. [15]. Standardization of HV was
based on the table provided by Tanner et al.
[15]. We required three visits pre- and post-
switch; when visits did not fall into the exact
time position, we interpolated the data; we used
the closest before and after height
measurements to the time position of need
and calculated the height point.
Statistical Analysis
Descriptive statistical analysis was performed
using SAS Version 9.2 (SAS Institute Inc., Cary,
NC, USA). Continuous parameters were
summarized using descriptive statistics
including mean and SD. Categorical
parameters were summarized using frequencies
and percentages. We conducted a quasi-
experimental analysis in which the subjects




A total of 103 patients were included in the
study: 57 patients with GHD, 26 with ISS, and
20 with TS. Patient baseline clinical
characteristics are summarized in Table 1.
There were slightly more pre-pubertal patients
than pubertal patients among the GHD and TS
patients, whereas the opposite occurred among
the ISS patients. Similarly, the pre-pubertal
patients were younger among the GHD and TS
groups than in the ISS children. The youngest
patient was 4-year old with TS. The mean total
dose of rhGH given to the patients was similar
among the three groups of patients during the
pre-pubertal and pubertal stages. The mean
duration patients were on a non-Omnitrope
rhGH therapy was 4.6 years (SD ±1.24 years,
minimum 1.52 years, maximum 5.84 years).
Height
The mean overall height at index date was
137.76 ± 18.72 cm for all patients, and the
mean height at 15 months post-switch for all
the patients was 144.28 ± 18.52 cm, showing an
increase of 6.52 cm (Table 2). Within each
category, the subjects’ mean height at the
index date was 137.37 ± 21.26 cm,
145.11 ± 14.75 cm, and 129.31 ± 10.68 cm for
the patients diagnosed with GHD, ISS, and TS,
respectively. After 15 months of Omnitrope
treatment, those with GHD grew (on average)
by 6.30 cm, those with ISS grew (on average) by
6.58 cm, and those with TS grew (on average) by
6.52 cm (Table 3). Height profiles of each
participant during the 15-month pre- and
post-switch period relative to the time of their
index date are shown in Figs. 1 (all patients) and
2 (by indication).
Height SDS
The mean HSDS for all subjects at index date
was -1.49 ± 1.01; HSDS increased by an average
of 0.04 over the 15-month post-switch period
(Table 2). Within each category, the subjects’
mean HSDS at the index date was -1.23 ± 1.06,
-1.70 ± 0.80, and -1.97 ± 0.90 for the patients
diagnosed with GHD, ISS, and TS, respectively.
Those with GHD improved, on average, by 0.07;
those with ISS improved, on average, by 0.13;
patients with TS had a change of -0.15
(Table 3). Figure 3 shows individual HSDS
profiles over time, and indicates little impact
on HSDS after the switch to Omnitrope,
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consistent with maintenance of growth during
post-switch.
Height Velocity
The mean HV for all patients at index date was
6.00 ± 1.93 cm/year. Over the 15-month post-
switch period, mean HV decreased by 1.06 cm/
year (Table 2). Within categories, the subjects’
mean HVs at the index date was
6.15 ± 2.13 cm/year, 5.90 ± 1.67 cm/year, and
5.71 ± 1.68 cm/year for the patients diagnosed
with GHD, ISS, and TS, respectively. Those with
GHD, ISS, and TS decelerated by 0.84 cm/year,
1.16 cm/year, and 1.62 cm/year, respectively
(Table 3).
Height Velocity SDS
The mean HVSDS for all patients was
0.78 ± 2.90 over the 15-month post-switch
period. During the initial 6 months, there was
an increase for all patients in HVSDS (at
3 months HVSDS was 1.03 ± 2.86, at 6 months
HVSDS was 1.16 ± 3.20); however, after
9 months the HVSDS for all patients declined
slightly (Table 2; Fig. 4). This could be
contributed to the advancing age. The patients
mean HVSDS declined by an average of 0.52
over the 15-month post-switch period (Table 2;
Fig. 4). The subjects’ mean body HVSDS at the
index date within each category was
0.71 ± 3.08, 1.45 ± 2.56, and 0.13 ± 2.75 for
the patients diagnosed with GHD, ISS and TS,
respectively (Table 3; Fig. 4). Those with GHD
declined, on average, by 0.33. Those with ISS
declined, on average, by 0.59. Patients with TS
declined, on average, by 0.85.
DISCUSSION
This present study has used real-world
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Table 2 Summary of height, HSDS, HV, and HVSDS 15 months pre- and post-switch (all patients)
All patients Height (cm) HSDS HV (cm/year)a HVSDS
Time N Mean – SD N Mean – SD N Mean – SD N Mean – SD
15 months prior 103 130.05 ± 19.32 103 -1.62 ± 1.07 – – – –
12 months prior 103 131.76 ± 19.18 103 -1.58 ± 1.04 – – – –
9 months prior 103 133.30 ± 19.09 103 -1.55 ± 1.04 – – – –
6 months prior 103 134.79 ± 18.89 103 -1.53 ± 1.06 100 6.43 ± 2.33 99 0.89 ± 3.17
3 months prior 103 136.25 ± 18.81 103 -1.52 ± 1.04 103 6.19 ± 2.23 100 0.82 ± 3.08
Switch 103 137.76 ± 18.72 103 -1.49 ± 1.01 103 6.00 ± 1.93 99 0.78 ± 2.90
3 months post 103 139.31 ± 18.65 102 -1.47 ± 1.01 103 6.02 ± 2.00 99 1.03 ± 2.86
6 months post 103 140.68 ± 18.62 102 -1.46 ± 1.01 103 5.88 ± 2.05 97 1.16 ± 3.20
9 months post 103 141.80 ± 18.70 101 -1.47 ± 1.01 103 5.55 ± 2.19 94 0.82 ± 3.42
12 months post 101 143.20 ± 18.41 99 -1.46 ± 1.01 101 5.33 ± 2.29 90 0.59 ± 3.37
15 months post 98 144.28 ± 18.52 95 -1.45 ± 1.01 98 4.94 ± 2.17 87 0.26 ± 3.21
HSDS Height standard deviation score, HV height velocity, HVSDS height velocity standard deviation score
a HV and HVSDS demonstrate the expected decline associated with advancing age
Table 3 Summary for height, HSDS, HV, and HVSDS 15 months pre- and post-switch (by indication)
Time Height (cm) HSDS HV (cm/year)a HVSDS
N Mean – SD N Mean – SD N Mean – SD N Mean – SD
GHD
15 months prior 57 129.51 ± 22.05 57 -1.36 ± 1.18 – – – –
12 months prior 57 131.22 ± 21.90 57 -1.33 ± 1.13 – – – –
9 months prior 57 132.74 ± 21.73 57 -1.31 ± 1.10 – – – –
6 months prior 57 134.31 ± 21.40 57 -1.28 ± 1.13 54 6.40 ± 2.50 54 0.51 ± 2.92
3 months prior 57 135.84 ± 21.36 57 -1.26 ± 1.10 57 6.31 ± 2.33 55 0.73 ± 3.10
Switch 57 137.37 ± 21.26 57 -1.23 ± 1.06 57 6.15 ± 2.13 54 0.71 ± 3.08
3 months post 57 138.97 ± 21.18 56 -1.22 ± 1.05 57 6.24 ± 2.01 54 1.05 ± 3.02
6 months post 57 140.43 ± 21.05 56 -1.22 ± 1.03 57 6.11 ± 2.19 54 1.22 ± 3.51
9 months post 57 141.65 ± 21.10 56 -1.21 ± 1.01 57 5.82 ± 2.38 54 1.06 ± 3.82
12 months post 56 142.63 ± 21.10 55 -1.19 ± 1.01 56 5.61 ± 2.36 51 0.68 ± 3.57
15 months post 55 143.67 ± 21.05 53 -1.16 ± 1.01 55 5.31 ± 2.23 50 0.38 ± 3.38
ISS
15 months prior 26 137.51 ± 14.79 26 -1.87 ± 0.82 – – – –
12 months prior 26 139.21 ± 14.74 26 -1.82 ± 0.81 – – – –
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patients switching from a non-Omnitrope
rhGH to Omnitrope in an US integrated
healthcare system. Our findings indicate that
such a switch can be conducted without
negatively impacting the growth trajectories
of the treated patients. This applies to the
overall study population and also when
considering the indication-specific subgroups
(GHD, TS, ISS).
Patients were on a non-Omnitrope rhGH
therapy for a mean duration of 4.6 years (SD
±1.24 years, minimum 1.52 years, maximum
5.84 years) and it has been shown in previous
studies [16–20] that administration of growth
hormone to children with GHD or ISS results in
marked acceleration in linear growth, mostly
during the first years of treatment. After
4–10 years of treatment, the HSDS increase
Table 3 continued
Time Height (cm) HSDS HV (cm/year)a HVSDS
N Mean – SD N Mean – SD N Mean – SD N Mean – SD
9 months prior 26 140.86 ± 14.95 26 -1.77 ± 0.84 – – – –
6 months prior 26 142.34 ± 14.89 26 -1.74 ± 0.85 26 7.06 ± 2.20 25 2.47 ± 3.63
3 months prior 26 143.65 ± 14.85 26 -1.73 ± 0.84 26 6.13 ± 2.01 25 1.43 ± 2.97
Switch 26 145.11 ± 14.75 26 -1.70 ± 0.80 26 5.90 ± 1.67 25 1.45 ± 2.56
3 months post 26 146.73 ± 14.66 26 -1.63 ± 0.80 26 5.88 ± 1.97 25 1.78 ± 2.27
6 months post 26 148.17 ± 14.68 26 -1.59 ± 0.81 26 5.81 ± 1.94 23 2.08 ± 2.59
9 months post 26 149.29 ± 14.62 25 -1.56 ± 0.82 26 5.64 ± 2.04 20 1.62 ± 2.42
12 months post 26 150.56 ± 14.43 25 -1.53 ± 0.81 26 5.45 ± 2.31 20 1.61 ± 2.68
15 months post 25 151.69 ± 14.41 24 -1.57 ± 0.80 25 4.74 ± 2.15 19 0.86 ± 2.44
TS
15 months prior 20 121.88 ± 11.72 20 -2.03 ± 0.83 – – – –
12 months prior 20 123.61 ± 11.31 20 -1.98 ± 0.87 – – – –
9 months prior 20 125.05 ± 11.02 20 -1.96 ± 0.91 – – – –
6 months prior 20 126.33 ± 10.99 20 -1.99 ± 0.91 20 5.70 ± 1.83 20 -0.08 ± 2.62
3 months prior 20 127.82 ± 10.70 20 -1.98 ± 0.93 20 5.93 ± 2.27 20 0.28 ± 3.17
Switch 20 129.31 ± 10.68 20 -1.97 ± 0.90 20 5.71 ± 1.68 20 0.13 ± 2.75
3 months post 20 130.63 ± 10.37 20 -1.97 ± 0.92 20 5.58 ± 2.00 20 0.06 ± 2.92
6 months post 20 131.68 ± 10.52 20 -2.03 ± 0.92 20 5.34 ± 1.75 20 -0.06 ± 2.65
9 months post 20 132.50 ± 10.72 20 -2.10 ± 0.94 20 4.68 ± 1.58 20 -0.61 ± 2.78
12 months post 19 134.78 ± 9.61 19 -2.17 ± 0.95 19 4.35 ± 1.86 19 -0.73 ± 3.21
15 months post 18 135.83 ± 9.89 18 -2.12 ± 0.95 18 4.09 ± 1.81 18 -0.72 ± 3.38
a HV and HVSDS demonstrate the expected decline associated with advancing age
GHD Growth hormone deﬁciency, HSDS height standard deviation score, HV height velocity, HVSDS height velocity
standard deviation score, ISS idiopathic short stature, TS Turner syndrome
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Fig. 1 Individual height proﬁles versus time from the switch
Fig. 2 Individual height proﬁles versus time from the switch by indication. GHD Growth hormone deﬁciency, ISS
idiopathic short stature, TS Turner syndrome
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wanes and does not differ significantly from the
predicted score in the absence of therapy [16–
20]. In this study, patients continued to grow in
height and HSDS in all categories from index to
15 months post-switch. Results are expected
and understandable given the age, overall
duration of GH treatment, and pubertal status
of the study population [16–20]. The mean HV
for all patients in the study was 6.00 ± 1.93 cm/
year over the 15-month post-switch period and
is consistent with other reports of patients at
similar durations of treatment [16, 17]. We
recognize that the GH therapy dose that was
used in TS patients pre- and post-switch was less
than the recommended dose of 0.375 mg/kg/
week. Nonetheless, patients’ individual height
profiles were maintained after the switch. The
overall growth rate for all the patients was
similar with the similar GH dosages, and this
may be due to how we identified the diagnosis
codes for each patient in GH therapy. However,
we reviewed the chart for each patient and tried
Fig. 3 Height standard deviation score (HSDS) versus time from switch for all patients, and by indication. GHD Growth
hormone deﬁciency, ISS idiopathic short stature, TS Turner syndrome
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to ensure that the diagnosis was categorized
correctly.
Physicians are often faced with the need to
change rhGH therapy, due to health plan and/
or changes to a patient’s insurance, and this
may be a cause of concern. Previous studies that
have examined the impact of switching rhGH
products have focused on parameters such as
physician attitudes or the administrative
burden on clinics, with the suggestion that
patient care may be negatively impacted [21].
Alternatively, a comparative analysis of data
from phase 3 studies demonstrated that
switching rhGH therapy (from Genotropin to
Omnitrope) has no impact on efficacy or safety
in children with GHD [22]. More recently, a
study from Sweden showed that patients with a
range of pediatric growth disturbances could be
successfully switched from Genotropin to
Omnitrope, with no negative impact on
growth and no serious or unexpected adverse
drug reactions [23].
A limitation of our study is the retrospective
nature of the analyses. Nevertheless, reporting
of real-world data is of great value. We cannot
exclude the possibility of inaccurate entry of
data in the eMR system, although this
possibility is equally likely to have occurred
pre- and post-switch. We also required three
visits that were 3 months apart during pre- and
post-switch; however, some visits did not fall
into the exact time position. We interpolated
the data for some of these time positions using
the closest height measurements before and
after the time position of need, and calculated
the height point.
CONCLUSION
This study used real-world retrospective data to
examine the impact of switching from a non-
Omnitrope rhGH to Omnitrope. The study
demonstrated that patients continued to grow
without alteration in their growth trajectories
and can therefore be switched from a non-
Omnitrope rhGH to Omnitrope without any
negative impact on their growth. Our findings
should be a useful resource for physicians who
are faced with the possibility of switching rhGH
therapy.
Fig. 4 Height velocity standard deviation score for all patients
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